“Neurofibromatosis type 2: Molecular and clinical analyses in

FERRER MARCELA, ; SCHULZE ALJOSCHA, ; GONZALEZ SERGIO, ; FERREIRO VERÓNICA, ; CIAVARELLI PATRICIA, ; OTERO JOSÉ, ; GILIBERTO FLORENCIA, ; BASSO ARMANDO, ; SZIJAN IRENE.

NEUROSCIENCE LETTERS - SUPPLEMENT

Amsterdam, Elsevier/North-Holland.

Lugar: Amsterdam, Elsevier/North-Holland.; Año: 2010 vol. 480 p. 49 - 54

0167-6253

Neurofibromatosis 2 is a familial syndrome characterized by the development of schwannomas, meningiomas and ependymomas. Most of them are benign however, their location in the nervous system has harmful effects on important cranial and spinal structures. These tumors are developed as the outcome of NF2 gene (22q12) inactivation. The NF2 protein, merlin or schwannomin belongs to the Ezrin, Radixin, Moesin (ERM) family involved in the cytoskeletal network and has a tumor suppressor function. Inactivating mutations occur as "de novo" (more frequently) or as inherited, and most of them are frameshift or nonsense. Our aim is to study NF2 gene alterations in Argentine patients and relate them to clinical features. 10 families and 29 single patients were analyzed for: 1) at-risk haplotype by STR-segregation analysis and 2) NF2 gene mutations by SSCP/heteroduplex/sequencing. The at-risk haplotype was uncovered in 8 families and mutations were identified in 5 patients. The molecular data are in full agreement with the clinical features supporting previous reports. The obtained results were important for the detection of mutation-carrying relatives and exclusion of other individuals from risk. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.